Skip to main content

Table 1 Association between clinicopathologic factors and the expression of programmed cell death-ligand 1 (PD-L1) and programmed cell death-ligand 2 (PD-L2) in primary tumors and metastatic lymph nodes from patients with gastric adenocarcinoma

From: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma

Variable Total (cases) PD-L1 expression [cases (%)] PD-L2 expression [cases (%)]
Primary tumors Metastatic lymph nodes Primary tumors Metastatic lymph nodes
Negative Positive P Negative Positive P Negative Positive P Negative Positive P
Total 119 73 46   65 54   85 34   87 32  
Sex    0.102   0.352   0.904   0.991
 Male 78 52 (66.7) 26 (33.3)   45 (57.7) 33 (42.3)   56 (71.8) 22 (28.2)   57 (73.1) 21 (26.9)  
 Female 41 21 (51.2) 20 (48.8)   20 (48.8) 21 (51.2)   29 (70.7) 12 (29.3)   30 (73.2) 11 (26.8)  
Age (years)     0.781    0.450    0.911    0.122
 <55 55 33 (60.0) 22 (40.0)   28 (50.9) 27 (49.1)   39 (70.9) 16 (29.1)   44 (80.0) 11 (20.0)  
 ≥55 64 40 (62.5) 24 (37.5)   37 (57.8) 27 (42.2)   46 (71.9) 18 (28.1)   43 (67.2) 21 (32.8)  
Tumor location     0.289    0.878    0.537    0.552
 Cardia 49 34 (69.4) 15 (30.6)   28 (57.1) 21 (42.9)   37 (75.5) 12 (24.5)   38 (77.6) 11 (22.4)  
 Body 20 12 (60.0) 8 (40.0)   11 (55.0) 9 (45.0)   15 (75.0) 5 (25.0)   15 (75.0) 5 (25)  
 Antrum 50 27 (54.0) 23 (46.0)   26 (52.0) 24 (48.0)   33 (66.0) 17 (34.0)   34 (68.0) 16 (32.0)  
Cell differentiation     0.952    0.822    0.114    0.202
 Well to moderate 21 13 (61.9) 8 (38.1)   11 (52.4) 10 (47.6)   12 (57.1) 9 (42.9)   13 (61.9) 8 (38.1)  
 Poor (including Signet ring cell) 98 60 (61.2) 38 (38.8)   54 (55.1) 44 (44.1)   73 (74.5) 25 (25.5)   74 (75.5) 24 (24.5)  
Lauren classification     0.032    0.028    0.119    0.005
 Intestinal 60 31 (51.7) 29 (48.3)   27 (45.0) 33 (55.0)   39 (65.0) 21 (35.0)   37 (61.7) 23 (38.3)  
 Diffuse and mixed 59 42 (71.2) 17 (28.8)   38 (64.4) 21 (35.6)   46 (78.0) 13 (22.0)   50 (84.7) 9 (15.3)  
Vascular invasion     0.011    0.009    0.011    0.003
 Yes 55 27 (49.1) 28 (50.9)   23 (41.8) 32 (58.2)   33 (60.0) 22 (40.0)   33 (60.0) 22 (40.0)  
 No 64 46 (71.9) 18 (28.1)   42 (65.6) 22 (34.4)   52 (81.3) 12 (18.8)   54 (84.4) 10 (15.6)  
Neural invasion     0.381    0.679    0.001    0.004
 Yes 77 45 (58.4) 32 (41.6)   41 (53.2) 36 (46.8)   63 (81.8) 14 (18.2)   63 (81.8) 14 (18.2)  
 No 42 28 (66.7) 14 (33.3)   24 (57.1) 18 (42.9)   22 (52.4) 20 (47.6)   24 (57.1) 18 (42.9)  
Clinical stage     0.099    0.377    0.336    0.400
 II–IIIA 12 10 (83.3) 2 (16.7)   8 (66.7) 4 (33.3)   10 (83.3) 2 (16.7)   10 (83.3) 2 (16.7)  
 IIIB–IIIC 107 63 (58.9) 44 (41.1)   57 (53.3) 50 (46.7)   75 (70.1) 32 (29.9)   77 (72.0) 30 (28.0)